Amlodipine/Candesartan/Indapamide (Shin Poong Pharmaceutical)
- Generic Name
- Amlodipine/Candesartan/Indapamide (Shin Poong Pharmaceutical)
Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension
Phase 2
Completed
- Conditions
- HypertensionEssential Hypertension
- Interventions
- Drug: SPC1001 HighDrug: SPC1001 Mid1Drug: SPC1001 Mid2Drug: SPC1001 LowDrug: SPC4001Drug: SPC4002Drug: Placebo
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
- Target Recruit Count
- 253
- Registration Number
- NCT06212648
- Locations
- 🇰🇷
CHA Gangnam Medical Center, CHA University, Seoul, Gangnam, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath